CVS HEALTH CORP

CVS Health Q2 2026 revenue hits $106.1B, EPS up to $2.58, and the company lifts its full‑year earnings outlook amid stronger pharmacy‑benefits and Aetna growth.

CVS Health’s latest moves to standardize prior‑authorization rules with UnitedHealth, a 3.2% share rise, and a PR spat with Planned Parenthood highlight its growing influence and investor appeal in the health‑care market.

CVS Health Corp sees a surge in institutional buying, steep options volume, and a price‑target cut amid a strategic pivot and FTC scrutiny—can the pharmacy giant navigate this turbulence?…

CVS Health’s stock drops as institutional selling, a CEO retirement and a new pharmacy‑only store rollout raise investor uncertainty. Find out how the strategy could reshape community care.

CVS Health’s recent $10B Oak Street Health deal sparks insider‑trading claims and a $45M PBM settlement, testing its growth plans amid rising regulatory scrutiny.

CVS Health Corp’s latest moves—TrumpRx expansion, Aetna’s award and mixed institutional trading—show a high‑valuation play seeking growth amid PBM volatility.

CVS Health’s new TrumpRx partnership, biosimilar swaps, and veteran‑access plan show how the pharmacy giant is reshaping drug pricing, cutting costs and boosting competition while facing regulatory scrutiny and investor pressure.

CVS Health’s new $91 target from Bernstein shows bullish outlook amid insider‑trading probe—explore how its diversified pharmacy‑benefit model drives future growth.

CVS Health’s January 10 earnings call will reveal 2025 guidance, revenue trends, cost‑cutting plans and digital‑health strategy, guiding investors and customers alike.

CVS Health’s latest share‑holding shift signals investors eyeing PBM, specialty‑drug, and digital‑pharmacy trends amid rising competition and regulatory scrutiny.